HomeCompareCBLNY vs JNJ

CBLNY vs JNJ: Dividend Comparison 2026

CBLNY yields 4.23% · JNJ yields 2.13%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 CBLNY wins by $2442.38M in total portfolio value
10 years
CBLNY
CBLNY
● Live price
4.23%
Share price
$5.10
Annual div
$0.22
5Y div CAGR
100%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$2442.41M
Annual income
$2,336,327,465.61
Full CBLNY calculator →
JNJ
Johnson & Johnson
● Live price
2.13%
Share price
$244.44
Annual div
$5.20
5Y div CAGR
28%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$30.3K
Annual income
$4,689.40
Full JNJ calculator →

Portfolio growth — CBLNY vs JNJ

📍 CBLNY pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodCBLNYJNJ
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, CBLNY + JNJ cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
CBLNY pays
JNJ pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

CBLNY
Annual income on $10K today (after 15% tax)
$359.62/yr
After 10yr DRIP, annual income (after tax)
$1,985,878,345.77/yr
JNJ
Annual income on $10K today (after 15% tax)
$180.82/yr
After 10yr DRIP, annual income (after tax)
$3,985.99/yr
At 15% tax rate, CBLNY beats the other by $1,985,874,359.78/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of CBLNY + JNJ for your $10,000?

CBLNY: 50%JNJ: 50%
100% JNJ50/50100% CBLNY
Portfolio after 10yr
$1221.22M
Annual income
$1,168,166,077.50/yr
Blended yield
95.66%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on JNJ right now

CBLNY
No analyst data
Altman Z
2.6
Piotroski
4/9
JNJ
Analyst Ratings
20
Buy
17
Hold
3
Sell
Consensus: Buy
Price Target
$228.73
-6.4% upside vs current
Range: $190.00 — $265.00
Altman Z
5.2
Piotroski
4/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

CBLNY buys
0
JNJ buys
8
PoliticianChamberTickerTypeAmountDate
Thomas H. Kean🏢 House$JNJ▼ Sell$15,001 - $50,0002026-01-23
Julie Johnson🏢 House$JNJ▼ Sell$1,001 - $15,0002025-12-18
Lloyd Doggett🏢 House$JNJ▲ Buy$1,001 - $15,0002025-12-09
Thomas H. Kean🏢 House$JNJ▼ Sell$15,001 - $50,0002025-11-20
Julie Johnson🏢 House$JNJ▼ Sell$1,001 - $15,0002025-11-13
Rich McCormick🏢 House$JNJ▲ Buy$1,001 - $15,0002025-11-05
Ro Khanna🏢 House$JNJ▲ Buy$1,001 - $15,0002025-10-30
Ro Khanna🏢 House$JNJ▲ Buy$1,001 - $15,0002025-10-30
Ro Khanna🏢 House$JNJ▲ Buy$1,001 - $15,0002025-10-30
Jared Moskowitz🏢 House$JNJ▼ Sell$1,001 - $15,0002025-10-10
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricCBLNYJNJ
Forward yield4.23%2.13%
Annual dividend / share$0.22$5.20
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR100%28%
Portfolio after 10y$2442.41M$30.3K
Annual income after 10y$2,336,327,465.61$4,689.40
Total dividends collected$2434.86M$15.4K
Payment frequencyquarterlyquarterly
SectorStockHealthcare

Year-by-year: CBLNY vs JNJ ($10,000, DRIP)

YearCBLNY PortfolioCBLNY Income/yrJNJ PortfolioJNJ Income/yrGap
1← crossover$11,546$846.16$10,592$272.30+$954.00CBLNY
2$14,181$1,826.14$11,289$357.73+$2.9KCBLNY
3$19,365$4,192.14$12,123$472.89+$7.2KCBLNY
4$31,422$10,700.74$13,141$629.86+$18.3KCBLNY
5$66,075$32,453.71$14,408$846.81+$51.7KCBLNY
6$198,261$127,561.06$16,021$1,151.60+$182.2KCBLNY
7$927,567$715,427.77$18,122$1,588.22+$909.4KCBLNY
8$7,248,829$6,256,331.97$20,930$2,228.20+$7.23MCBLNY
9$99,144,099$91,387,852.40$24,792$3,191.91+$99.12MCBLNY
10$2,442,411,652$2,336,327,465.61$30,274$4,689.40+$2442.38MCBLNY

CBLNY vs JNJ: Complete Analysis 2026

CBLNYStock

Mersen SA manufactures and sells electrical power products and advanced materials in France, North America, rest of Europe, the Asia-Pacific, and internationally. It operates through Advanced Materials and Electrical Power segments. The company offers electrical protection and control products, such as IEC and UL/CSA low voltage general purpose fuses and fuse gears, high and medium voltage fuses, and power transfer solutions for rail vehicles, as well as surge protection, lightning protection, and power monitoring solutions; and power management solutions, including high speed fuses, DC protection for electric vehicles and battery, cooling solutions, bus bars, and aluminum electrolytic and film capacitors. It also provides anticorrosion equipment comprising heat exchangers; columns, reactors, and pressure vessels; PTFE or PFA bellows, pipes, elbows, and fittings; graphite bursting discs; corrosion resistant materials; and after-sales and maintenance services, as well as graphite specialties, such as isostatic graphite, carbon insulation, extruded graphite, carbon/carbon composites, silicon carbide, and flexible graphite. In addition, the company offers carbon brushes, brush-holders, brush-rockers and brush gear housings, signal and power transmission systems, rotary joints, current collectors, wheel flange lubrication solutions, carbon dust collection systems, and monitoring solutions, as well as slip, pitch control, and electrical ring assemblies. It serves energy, electronics, transportation, corrosive chemicals, and process industries, as well as other markets comprising building, elevator, ski lifts, defense, HVAC, and outdoor LED lighting markets. The company was formerly known as Groupe Carbone Lorraine SA and changed its name to Mersen SA in 2010. Mersen SA was founded in 1889 and is headquartered in Courbevoie, France.

Full CBLNY Calculator →

JNJHealthcare

Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the healthcare field worldwide, but strategically separated its Consumer Health business into Kenvue Inc. in 2023 to focus on its higher-growth, innovation-driven segments; the former Consumer Health brands (including TYLENOL, LISTERINE, and BAND-AID) are now owned by Kenvue. The company's core focus is now split between its Innovative Medicine (formerly Pharmaceutical) segment, which offers prescription products for complex diseases such as rheumatoid arthritis, various cancers, HIV/AIDS, and neurodegenerative disorders; and its MedTech (Medical Devices) segment, which provides advanced technology solutions including electrophysiology products, neurovascular care products, orthopaedics (hips, knees, spine), advanced surgery solutions, and disposable contact lenses under the ACUVUE brand. Company's two remaining segments primarily serve hospitals, healthcare professionals, wholesalers, and retailers, continuing its mission of advancing human health since its founding in 1886 and its current basing in New Brunswick, New Jersey.

Full JNJ Calculator →
📬

Get this CBLNY vs JNJ comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

CBLNY vs SCHDCBLNY vs JEPICBLNY vs OCBLNY vs KOCBLNY vs MAINCBLNY vs ABBVCBLNY vs MRKCBLNY vs PFE

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.